Loading...
•
Dec 31, 2021
Insulet Q4 2021 Earnings Report
Insulet reported a Q4 2021 revenue increase of 25% year-over-year.
Key Takeaways
Insulet Corporation reported a strong fourth quarter in 2021, with revenue reaching $307.7 million, a 25% increase compared to the previous year. The company's success was driven by significant growth in U.S. Omnipod and Drug Delivery revenue, contributing to an operating income of $49.7 million and a net income of $29.2 million.
Revenue increased by 25% to $307.7 million, exceeding the guidance range.
U.S. Omnipod revenue increased by 27.7%.
Drug Delivery revenue increased by 112.7%.
The company received U.S. FDA clearance for the Omnipod® 5 automated insulin delivery system.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
Insulet expects revenue growth for the year ending December 31, 2022, to be in the range of 12% to 16%. For the quarter ending March 31, 2022, the Company expects revenue growth of 13% to 16%.
Positive Outlook
- Total Omnipod revenue is expected to grow by 15% to 20%.
- U.S. Omnipod revenue is expected to grow by 18% to 23%.
- International Omnipod revenue is expected to grow by 9% to 14%.
- Drug Delivery revenue is expected to decline by 35% to 30%.
- Operating margin growth of approximately 100 basis points is expected.
Challenges Ahead
- Drug Delivery revenue is expected to decline by 35% to 30%.
- International Omnipod revenue is expected to grow by 9% to 14%.
- Total Omnipod of 13% to 16%
- U.S. Omnipod of 17% to 20%
- International Omnipod of 6% to 10%
Revenue & Expenses
Visualization of income flow from segment revenue to net income